Latest MS research news

Featured

Global response to progressive MS challenge

Global experts from the Progressive MS Alliance are meeting in London in April and May to review the applications they have received for funding.

From MSIF

Latest MS research news | 22 April 2014

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

Atacicept treatment in MS is associated with a reduction in serum immunoglobulin concentrations and numbers of circulating mature B cells, but with an increase in relapses.

From MSIF

Latest MS research news | 22 April 2014

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis

This document provides a guide to the most known complementary and alternative medicine therapies used in MS including oral cannabinoids, sativex oromucosal cannabinoid spray, ginkgo biloba, reflexology and magnetic therapy.

From MSIF

Latest MS research news | 15 April 2014

Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and MS lesions

The study provides the first comprehensive overview of the cellular distribution of key nutrient transporters (i.e. glucose and monocarboxylate transporters) in white matter brain samples in the central nervous system tissue of non-neurological and MS patients.

From MSIF

Latest MS research news | 15 April 2014

Oral ponesimod in relapsing–remitting MS: a randomised phase II trial

Once-daily treatment with ponesimod significantly reduces new lesion onset and shows a beneficial clinical effect in patients with RRMS. The treatment is also associated with a lower annualised relapse rate and an increase in the time to first confirmed relapse. Ponesimod is generally well tolerated, but 24-week treatment duration of this study limits the provision of long-term safety and clinical efficacy data.

From MSIF

Latest MS research news | 15 April 2014

Safety and efficacy of fingolimod in patients with relapsing-remitting MS

The study confirms that fingolimod can improve relapse-related outcomes and reduce brain volume loss compared to patients treated with placebo, while it doesn’t shows a statistically significant effect on disability progression.

From MSIF

Latest MS research news | 08 April 2014

Isolated cognitive relapses in MS

This study investigated the relevance of isolated cognitive relapses in patients with relapsing-remitting MS. The researchers defined an isolated cognitive relapse as a transient reduction in cognitive functioning not associated with other subjective or objective neurological symptoms.

From MSIF

Latest MS research news | 08 April 2014

JC virus reactivation during prolonged natalizumab monotherapy for MS

This study looks at getting a better understanding of the virus which causes PML (Progressive Multifocal Leucoencephalopathy) in patients treated with natalizumab (tysabri).

From MSIF

Latest MS research news | 08 April 2014

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

This study shows that natalizumab (tysabri) treatment in progressive MS reduces central nervous system (CNS) inflammation and tissue damage.

From MSIF

Latest MS research news | 01 April 2014

Composite end points to assess delay of disability progression by MS treatments

Monitoring progression of disease in MS can be difficult particularly in clinical trials. The Expanded Disability Status Scale (EDSS) is most commonly used. The results from this study showed that using composite end points (combination of two or more end points) such as the timed-25 foot walk test and the nine-hole peg test may be better than using the EDSS alone in monitoring disease progression.

From MSIF

Latest MS research news | 01 April 2014

Posterior brain damage and cognitive impairment in paediatric MS

Paediatric patients with MS can experience cognitive impairment, with a prominent involvement of linguistic abilities in addition to memory, attention and executive function. This study looked at improving our understanding of the mechanisms involved in memory difficulties in paediatric patients with MS. Overall, the results showed that the posterior regions of the brain were most likely to be abnormal on structural and functional MRI.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial